Comparing the current results to its competitors, Allogene Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 567.5 % year on year. The sales growth was above Allogene Therapeutics Inc 's competitors' average revenue growth of 11.54 %, achieved in the same quarter.
Allogene Therapeutics Inc 's Comment on Competition and Industry Peers
The oncology market is highly competitive, with the company's products facing competition from therapies developed or in development by biopharmaceutical companies, academic institutions, governmental agencies, and research institutions. Competitors include existing and emerging cell-based therapies, both autologous and allogeneic, as well as other therapeutic modalities such as antibodies, bispecific T cell engagers, antibody-drug conjugates, and small molecule therapeutics. There is rapid development and commercialization of bispecific antibodies and other off-the-shelf immune oncology products that may compete with the company's programs. Numerous companies are developing allogeneic T cell products targeting antigens such as CD19, BCMA, and CD70. Other cell therapies based on different cell types are also under development. The company faces additional competition in autoimmune disease cell therapy development from various firms. Many competitors, including AstraZeneca, plc; Atara Biotherapeutics, Inc.; Beam Therapeutics, Inc.; Caribou Biosciences, Inc.; CRISPR Therapeutics AG; Editas Medicine, Inc.; F. Hoffmann-La Roche AG; Fate Therapeutics, Inc.; Gilead Sciences, Inc.; Imugene Ltd.; Intellia Therapeutics, Inc.; Legend Biotech Corp.; Precision Biosciences, Inc.; Sana Biotechnology, Inc.; Cellectis; Adicet Bio, Inc.; Artiva Biotherapeutics, Inc.; Carisma Therapeutics, Inc.; Cytovia Therapeutics, Inc.; Celularity, Inc.; Century Therapeutics, Inc.; Gamida Cell Ltd.; In8bio, Inc.; Lyell Immunopharma, Inc.; Nkarta; Arcellx, Inc.; Autolus Therapeutics plc; BMS; Cabaletta Bio, Inc.; Cartesian Therapeutics, Inc.; Gracell Biotechnologies, Inc.; ImmPACT Bio USA, Inc.; Kyverna Therapeutics, Inc.; and Novartis, possess greater financial resources and research expertise.
Due to outstanding performance in Overall company, revenue grew by 567.5 % Allogene Therapeutics Inc improved its market share, to approximately 0.06 %.
November 18, 2024
The Promising Path of Allogene Therapeutics: Exploring Dual CAR T Cell Therapy and Pivotal TrialsAllogene Therapeutics, Inc. is at the forefront of developing allogeneic CAR T (AlloCAR T) therapies, targeting both cancer and autoimmune diseases. Recent announcements and presentations have shed light on their innovative approaches, particularly with ALLO-329, an allogeneic dual CAR T targeting CD19 and CD70, and ALLO-316 for advanced renal cell carcinoma (RCC). The implications of these advances are significant for the company’s growth trajectory and the broader landscape of immunotherapy. 1. ALLO-329: Targeting Autoimmune Diseases At the American College of Rheumatology (ACR) Convergence 2024, Allogene Th...
July 1, 2024
Allogene Therapeutics Inc., a leading clinical-stage biotechnology company, has made significant progress in its mission to develop innovative allogeneic CAR T-cell (AlloCAR T) products for treating cancer. The company recently announced the activation of three community cancer centers for enrollment in the pivotal Phase 2 ALPHA3 trial, evaluating cemacabtagene ansegedleucel (cema-cel) as the first-line consolidation treatment for patients with large B-cell lymphoma (LBCL). Furthermore, at the 65th Annual Meeting of the American Society of Hematology (ASH), Allogene Therapeutics presented comprehensive safety data for their proprietary lymphodepletion agent ALLO-647, which was used in the Phase 1 ALPHA/ALPHA...
March 12, 2024
Allogene Therapeutics and Arbor Biotechnologies Collaborate to Advance Allogeneic CAR T Platform in Autoimmune Disease TreatmentIn an exciting development for the field of gene editing and autoimmune disease treatment, Allogene Therapeutics, Inc. and Arbor Biotechnologies, Inc. have announced a global gene editing licensing agreement. This collaboration will leverage Arbor s proprietary CRISPR gene-editing technology to support the advancement of Allogene s next-generation AlloCAR T platform for the treatment of autoimmune diseases.Allogene Therapeutics, a clinical-stage biotechnology company known for its pioneering work in allogeneic chimeric antigen receptor T cell (AlloCAR T) products, has been at the fo...
Allogene Therapeutics Inc., a pioneering clinical-stage biotechnology company focused on the advancement of allogeneic CAR T (AlloCAR T) products for battling cancer, has presented detailed safety data related to its proprietary lymphodepletion agent, ALLO-647, at the recently-concluded 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA. This presentation centered around a comprehensive safety review of patients who underwent treatment during the Phase 1 ALPHA/ALPHA2 trials featuring ALLO-501/501A. As an allogeneic CAR T player, Allogene Therapeutics uses engineered cells from healthy donors, contrasting with autologous CAR-T therapies from other developers that extract...
Publicly Traded Peers of Allogene Therapeutics Inc
Turnstone Biologics Corp Share Performance
-1.63%
30 Days
Turnstone Biologics Corp
Profile
Turnstone Biologics Corp is a biotechnology company that focuses on developing innovative cancer treatments. Their business model includes leveraging their proprietary vaccinia virus-based platform to engineer oncolytic viral immunotherapies. These therapies are designed to selectively target and destroy cancer cells while also activating the patient's immune system to generate a lasting anti-tumor response.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.
Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.
Sources:
Allogene Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Allogene Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
